Search

Search Constraints

You searched for: Author/Creator Butler, Matthew

Search Results

21. Long‐Term Safety Evaluation of Ubrogepant for the Acute Treatment of Migraine: Phase 3, Randomized, 52‐Week Extension Trial. Issue 1 (8th January 2020)

22. Neurological and psychiatric presentations associated with human monkeypox virus infection: A systematic review and meta-analysis. (October 2022)

23. Neurology and neuropsychiatry of COVID-19: a systematic review and meta-analysis of the early literature reveals frequent CNS manifestations and key emerging narratives. Issue 9 (3rd June 2021)

25. Persistent neuropsychiatric symptoms after COVID-19: a systematic review and meta-analysis. Issue 1 (17th December 2021)

26. Pharmacokinetics and safety of ubrogepant when coadministered with calcitonin gene‒related peptide‐targeted monoclonal antibody migraine preventives in participants with migraine: A randomized phase 1b drug–drug interaction study. Issue 4 (5th April 2021)

29. Safety and tolerability of ubrogepant following intermittent, high-frequency dosing: Randomized, placebo-controlled trial in healthy adults. (December 2019)